Cargando…

Metformin use and its effect on survival in diabetic patients with advanced non-small cell lung cancer

BACKGROUND: Previous population-based studies have demonstrated an association between metformin use and improved survival among diabetic patients with cancer. We sought to analyze the effects of diabetes and its treatment in terms of the survival of patients with lung cancer. METHODS: Overall, 1106...

Descripción completa

Detalles Bibliográficos
Autores principales: Arrieta, Oscar, Varela-Santoyo, Edgar, Soto-Perez-de-Celis, Enrique, Sánchez-Reyes, Roberto, De la Torre-Vallejo, Martha, Muñiz-Hernández, Saé, Cardona, Andrés F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4983059/
https://www.ncbi.nlm.nih.gov/pubmed/27519177
http://dx.doi.org/10.1186/s12885-016-2658-6
_version_ 1782447852541181952
author Arrieta, Oscar
Varela-Santoyo, Edgar
Soto-Perez-de-Celis, Enrique
Sánchez-Reyes, Roberto
De la Torre-Vallejo, Martha
Muñiz-Hernández, Saé
Cardona, Andrés F.
author_facet Arrieta, Oscar
Varela-Santoyo, Edgar
Soto-Perez-de-Celis, Enrique
Sánchez-Reyes, Roberto
De la Torre-Vallejo, Martha
Muñiz-Hernández, Saé
Cardona, Andrés F.
author_sort Arrieta, Oscar
collection PubMed
description BACKGROUND: Previous population-based studies have demonstrated an association between metformin use and improved survival among diabetic patients with cancer. We sought to analyze the effects of diabetes and its treatment in terms of the survival of patients with lung cancer. METHODS: Overall, 1106 patients with non-small cell lung cancer (94.3 % with stage IV disease) were included. The outcomes were compared between the patients with (n = 186) and without diabetes (n = 920). The characteristics associated with antidiabetic treatment and proper glycemic control (defined as a mean plasma glucose <130 mg/dL) were examined at diagnosis. The overall survivals (OSs) of the different patient populations were analyzed using Kaplan-Meier curves, and a multivariate Cox proportional hazard model was used to determine the influences of the patient and tumor characteristics on survival. RESULTS: The OS for the entire population was 18.3 months (95 % CI 16.1-20.4). There was no difference in the OSs of the diabetic and non-diabetic patients (18.5 vs 16.4 months, p = 0.62). The diabetic patients taking metformin exhibited a superior OS than did those on other antidiabetic treatments (25.6 vs 13.2 months, p = 0.017). Those with proper glycemic control had a better OS than did those without proper glycemic control and the non-diabetics (40.5 vs 13.2 and 18.5 months, respectively, p < 0.001). Both the use of metformin (HR 0.53, p < 0.0001 and HR 0.57, p = 0.017, respectively) and proper glycemic control (HR 0.49, p < 0.0001 and HR 0.40, p = 0.002, respectively) were significant protective factors in all and only diabetic patients, respectively. CONCLUSIONS: The diabetic patients with proper glycemic control exhibited a better OS than did those without proper glycemic control and even exhibited a better OS than did the patients without diabetes mellitus. Metformin use was independently associated with a better OS. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-016-2658-6) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4983059
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-49830592016-08-14 Metformin use and its effect on survival in diabetic patients with advanced non-small cell lung cancer Arrieta, Oscar Varela-Santoyo, Edgar Soto-Perez-de-Celis, Enrique Sánchez-Reyes, Roberto De la Torre-Vallejo, Martha Muñiz-Hernández, Saé Cardona, Andrés F. BMC Cancer Research Article BACKGROUND: Previous population-based studies have demonstrated an association between metformin use and improved survival among diabetic patients with cancer. We sought to analyze the effects of diabetes and its treatment in terms of the survival of patients with lung cancer. METHODS: Overall, 1106 patients with non-small cell lung cancer (94.3 % with stage IV disease) were included. The outcomes were compared between the patients with (n = 186) and without diabetes (n = 920). The characteristics associated with antidiabetic treatment and proper glycemic control (defined as a mean plasma glucose <130 mg/dL) were examined at diagnosis. The overall survivals (OSs) of the different patient populations were analyzed using Kaplan-Meier curves, and a multivariate Cox proportional hazard model was used to determine the influences of the patient and tumor characteristics on survival. RESULTS: The OS for the entire population was 18.3 months (95 % CI 16.1-20.4). There was no difference in the OSs of the diabetic and non-diabetic patients (18.5 vs 16.4 months, p = 0.62). The diabetic patients taking metformin exhibited a superior OS than did those on other antidiabetic treatments (25.6 vs 13.2 months, p = 0.017). Those with proper glycemic control had a better OS than did those without proper glycemic control and the non-diabetics (40.5 vs 13.2 and 18.5 months, respectively, p < 0.001). Both the use of metformin (HR 0.53, p < 0.0001 and HR 0.57, p = 0.017, respectively) and proper glycemic control (HR 0.49, p < 0.0001 and HR 0.40, p = 0.002, respectively) were significant protective factors in all and only diabetic patients, respectively. CONCLUSIONS: The diabetic patients with proper glycemic control exhibited a better OS than did those without proper glycemic control and even exhibited a better OS than did the patients without diabetes mellitus. Metformin use was independently associated with a better OS. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-016-2658-6) contains supplementary material, which is available to authorized users. BioMed Central 2016-08-12 /pmc/articles/PMC4983059/ /pubmed/27519177 http://dx.doi.org/10.1186/s12885-016-2658-6 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Arrieta, Oscar
Varela-Santoyo, Edgar
Soto-Perez-de-Celis, Enrique
Sánchez-Reyes, Roberto
De la Torre-Vallejo, Martha
Muñiz-Hernández, Saé
Cardona, Andrés F.
Metformin use and its effect on survival in diabetic patients with advanced non-small cell lung cancer
title Metformin use and its effect on survival in diabetic patients with advanced non-small cell lung cancer
title_full Metformin use and its effect on survival in diabetic patients with advanced non-small cell lung cancer
title_fullStr Metformin use and its effect on survival in diabetic patients with advanced non-small cell lung cancer
title_full_unstemmed Metformin use and its effect on survival in diabetic patients with advanced non-small cell lung cancer
title_short Metformin use and its effect on survival in diabetic patients with advanced non-small cell lung cancer
title_sort metformin use and its effect on survival in diabetic patients with advanced non-small cell lung cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4983059/
https://www.ncbi.nlm.nih.gov/pubmed/27519177
http://dx.doi.org/10.1186/s12885-016-2658-6
work_keys_str_mv AT arrietaoscar metforminuseanditseffectonsurvivalindiabeticpatientswithadvancednonsmallcelllungcancer
AT varelasantoyoedgar metforminuseanditseffectonsurvivalindiabeticpatientswithadvancednonsmallcelllungcancer
AT sotoperezdecelisenrique metforminuseanditseffectonsurvivalindiabeticpatientswithadvancednonsmallcelllungcancer
AT sanchezreyesroberto metforminuseanditseffectonsurvivalindiabeticpatientswithadvancednonsmallcelllungcancer
AT delatorrevallejomartha metforminuseanditseffectonsurvivalindiabeticpatientswithadvancednonsmallcelllungcancer
AT munizhernandezsae metforminuseanditseffectonsurvivalindiabeticpatientswithadvancednonsmallcelllungcancer
AT cardonaandresf metforminuseanditseffectonsurvivalindiabeticpatientswithadvancednonsmallcelllungcancer